Parameters | Deluzio et al. [10] | Lucio et al. [9] | Hartman et al. [26] | Gandhoke et al. [11] | The present study |
---|---|---|---|---|---|
Country | USA | USA | USA | USA | Thailand |
Type of analysis | Cost-effectiveness analysis | Cost-effectiveness analysis | Cost-effectiveness analysis | Cost-utility analysis | Cost-utility analysis |
Perspective | Provider | Provider | Provider | Societal | Societal |
Time horizon | 45 days | 45 days | 30 days | 2 years | Lifetime |
Patient data | 210 patients (109 LLIF, 101 PLIF) | 210 patients (109 LLIF, 101 PLIF) | 20 patients (10 LLIF, 10 TLIF) | 74 patients (29 LLIF, 45 TLIF) | 136 patients (59 LLIF, 77 PLIF) |
Costs | LLIF: 24,208 USD/patient | LLIF: 24,320 USD/patient | LLIF: 22,195 USD/patient | LLIF: 72,260 USD | LLIF: 30,124 USD |
PLIF: 26,770 USD/patient | PLIF: 27,055 USD/patient | TLIF: 29,951 USD/patient | TLIF: 65,179 USD | PLIF: 33,003 USD | |
Cost-saving 2563 USD/patient | Cost-saving 2825.37 USD/patient | Cost-saving 7756 USD/patient | |||
Utility assessment tool | N/A | N/A | N/A | EQ-5D-5L (2 years) | EQ-5D-5L (1 year) |
Utility results | |||||
LLIF | N/A | N/A | N/A | 0.60 | 0.84 |
PLIF | N/A | N/A | N/A | 0.67 | 0.89 |
QALYs | N/A | N/A | N/A | N/A | LLIF: 13.48 |
PLIF: 13.63 | |||||
ICERs | N/A | N/A | N/A | LLIF: 35,347 USD/QALY | LLIF versus PLIF 19,359 USD/QALY |
WTP per QALY | N/A | N/A | N/A | 100,000 USD/QALY | 5003 USD/QALY |